Drug Trial Radar · NCT06030804
Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
4,532
Planned (sponsor's estimate)
Start
Sep 12, 2023
Primary completion
Sep 2027
Study completion Oct 2030
Sponsor
- Lead sponsor
- Peking University First HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking University
- First posted
- Sep 11, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Along with aging population, cancer incidence and mortality are increasing. However, despite advances in oncology and surgery, long-term survival of cancer patients is far from optimal. Dexmedetomidine is a highly selective alpha 2 adrenergic receptor agonist with sedative, analgesic, and anxiolytic effects. Studies showed that perioperative use of dexmedetomidine reduces delirium and some non-delirium complications after surgery. In long-term follow-up studies of older patients who, for other reasons, were randomized to receive either dexmedetomidine or placebo during intra- or postoperative period, dexmedetomidine use was associated with improved long-term survival. This multicenter randomized trial aims to investigate the effect of perioperative dexmedetomidine on long-term outcomes in older patients undergoing cancer surgery.
Conditions
- Elderly
- Cancer Surgery
- Dexmedetomidine
- Long-Term Survivors
Interventions
DexmedetomidineDrug
A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
PlaceboDrug
Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival after surgeryTime frame: Up to 3 years after surgery of the last enrolled patient.
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of China University of Science and Technology
Hefei, Anhui, China · Recruiting
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Hefei, Anhui, China · Recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Tsinghua University Yuquan Hospital
Beijing, Beijing Municipality, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Army Medical University (Southwest Hospital)
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Provincial Hospital
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Not yet recruiting
Jinjiang City Hospital (Shanghai Sixth People's Hospital, Fujian Hospital)
Jinjiang, Fujian, China · Recruiting
Guangdong General Hospital
Guangzhou, Guangdong, China · Recruiting
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
The First Affiliated Hospital of Shenzhen University
Shenzhen, Guangdong, China · Recruiting
The Second Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Affiliated Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Zhejiang Cancer Hospital
Zhejiang, Hangzhou, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Tangshan Workers' Hospital
Tangshan, Hebei, China · Not yet recruiting
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
Xiangya Hospital Central South university
Changsha, Hunan, China · Recruiting
The First Affiliated Hospital of University of South China
Hengyang, Hunan, China · Not yet recruiting
Nanjing General Hospital of Nanjing Military Region
Nanjing, Jiangsu, China · Recruiting
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, China · Recruiting
Bethune First Hospital Of Jilin University
Changchun, Jilin, China · Recruiting
General hospital of eastern theater command
Nanjing, Nanjing, China · Not yet recruiting
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China · Not yet recruiting
People's Hospital of Ningxia Hui Autonomous Region
Yinchuan, Ningxia, China · Recruiting
Xijing Hospital, Fourth Military Medical University
Xi'an, Shaanxi, China · Recruiting
Shandong Provincial Hospital Heze Hospital
Heze, Shandong, China · Recruiting
Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Recruiting
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, China · Recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Recruiting
First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.